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Review Article
Celiac disease-on-chip: Modeling a
multifactorial disease in vitro
Rene´e Moerkens1, Joram Mooiweer1, Sebo Withoff1 and
Cisca Wijmenga1,2
Abstract
Conventional model systems cannot fully recapitulate the multifactorial character of complex diseases like celiac disease
(CeD), a common chronic intestinal disorder in which many different genetic risk factors interact with environmental factors
such as dietary gluten. However, by combining recently developed human induced pluripotent stem cell (hiPSC) technology
and organ-on-chip technology, in vitro intestine-on-chip systems can now be developed that integrate the genetic back-
ground of complex diseases, the different interacting cell types involved in disease pathology, and the modulating envir-
onmental factors such as gluten and the gut microbiome. The hiPSCs that are the basis of these systems can be generated
from both diseased and healthy individuals, which means they can be stratified based on their load of genetic risk factors.
A CeD-on-chip model system has great potential to improve our understanding of disease etiology and accelerate the
development of novel treatments and preventive therapies in CeD and other complex diseases.
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Introduction
Approximately 0.6% to 1%1 of the Caucasian popula-
tion has celiac disease (CeD), a complex immune-
mediated disease characterized by a strong inﬂammatory
reaction to dietary gluten in genetically predisposed indi-
viduals. CeD is a multifactorial disease caused by many
genetic and environmental risk factors. In addition to
gluten, viral infections2,3 and gut microbiome dysbiosis4
may also trigger disease onset. Although CeD is primar-
ily characterized by damage to the small intestine,
patients can also suﬀer from extraintestinal manifest-
ations such as anemia, osteoporosis and ataxia.5,6 The
large variation in presentation of symptoms leaves many
patients undiagnosed.7,8 After diagnosis, the only treat-
ment is lifelong adherence to a gluten-free diet, which
can reduce quality of life9 and may not totally prevent
gluten exposure because of ‘‘hidden’’ sources of gluten or
cross-contamination of food products.
To better understand the natural course of CeD and
design new preventive and treatment strategies, it is
imperative to develop sophisticated systems that recap-
itulate and model the disease. Such systems have not
been available thus far, but with recent molecular and
technological advances—speciﬁcally in human induced
pluripotent stem cell (hiPSC) technology, diﬀerenti-
ation protocols and organ-on-chip devices—these
complex modeling systems are now within reach.
In this review we illustrate the complexity of CeD
and describe how state-of-the-art stem cell and organ-
on-chip technology can provide an in vitro model for
CeD.
Pathogenesis of CeD
Immune response to gluten. The main trigger of CeD-
associated inﬂammation is dietary gluten, a storage
protein present in wheat, barley and rye. Gluten pro-
teins are rich in glutamine and proline residues that are
diﬃcult to digest.10 As a consequence, incompletely
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digested gluten peptides pass the epithelial layer of the
small intestine11 and enter the lamina propria where the
peptide fragments are deamidated by tissue transgluta-
minase 2 (TG2; Figure 1). Deamidated gluten peptides
have a higher aﬃnity to class II human leukocyte
antigen (HLA)-DQ2 or -DQ8 molecules on antigen-
presenting cells (APCs).12,13 APCs presenting deami-
dated gluten peptides strongly activate gluten-speciﬁc
CD4þT cells, which further elicit the pro-inﬂamma-
tory response characteristic of CeD. This response
drives B cell-mediated generation of TG2- and gluten-
speciﬁc antibodies that are used to diagnose CeD,13 and
licenses CD8þ intraepithelial lymphocytes (IELs) to
kill intestinal epithelial cells (IECs) leading to villous
atrophy.14 Key cytokines in these processes are inter-
feron-gamma,12 interleukin (IL)-1514 and IL-21.15
Genetic factors. Today, approximately 50% of the herit-
ability of CeD can be explained by 45 genetic risk factors
(Rican˜o-Ponce et al., manuscript in preparation). The
major genetic risk factors for CeD development are spe-
ciﬁc variants of the HLA class II genes (HLA-DQ2.5,
HLA-DQ2.2 and HLA-DQ8), and carriership is essen-
tial but not suﬃcient to trigger the disease.16 Genome-
wide association studies (GWAS) have identiﬁed 44
non-HLA risk factors, many of which are shared with
other immune-related diseases (e.g. type 1 diabetes,
rheumatoid arthritis, ulcerative colitis and Crohn dis-
ease).17,18 Most of these risk factors point to genes
involved in immune response and are expressed in dif-
ferent types of immune cells.19 However, a subset of the
genes are expressed in the intestinal barrier,20 suggesting
that barrier dysfunction plays a role in CeD.
Environmental factors and the microbiome. Because not all
carriers of genetic risk for CeD manifest the disease,
non-genetic environmental factors apart from gluten
may also play a role in disease onset. One such environ-
mental factor might be the amylase trypsin inhibitors
(ATIs) present in gluten-containing grains, because
these can trigger a Toll-like receptor 4-dependent
innate immune response in the small intestine.21
Additionally, viral infections (by rotaviruses, adeno-
virus, enteroviruses and hepatitis C virus) are associated
with increased incidence of CeD.22,23 Interestingly, a sig-
niﬁcant number of CeD-associated genetic loci harbor
transcription factor binding elements for gene products
of the Epstein-Barr virus, indicating one way that viruses
can regulate CeD-associated pathways.3 One of the few
published experimental studies showed that reovirus
infections can disrupt tolerance to gluten and other
food antigens in HLA-DQ8–expressing mice.2
Furthermore, the gut microbiome composition is
altered in CeD patients,24–26 which could be due to
genetic and environmental factors. On the one hand,
the HLA-DQ2 genotype introduces a selective pressure
on the developing intestinal microbiome in infants.27
On the other, a gluten-free diet changes the microbiome
composition of the intestine both in healthy adults and
adult CeD patients.28,29 These changes in gut microbial
composition can directly aﬀect processing of gluten
peptides.30,31 For example, CeD-associated bacteria
can produce shorter gluten peptides that more easily
translocate across the intestinal epithelial barrier, or
modify peptides so that they activate gluten-speciﬁc T
cells.4 Additionally, changes in the gut microbiome
induced by other environmental factors (such as anti-
biotic use, intestinal infections and cesarean delivery)
may indirectly contribute to CeD.25 Whether the micro-
biome is cause or consequence in CeD and how dysbio-
sis of the microbiome contributes to CeD are not clear.
Role of the intestinal barrier in CeD. It has been suggested






























Figure 1. Schematic overview of celiac disease (CeD) pathobiol-
ogy. Dietary gluten peptides pass the epithelial barrier, where they
become deamidated by tissue transglutaminase 2 (TG2). The dea-
midated gluten peptides are taken up by antigen presenting cells
(APCs) and are presented to CD4þ T cells, exclusively in the context
of human leukocyte antigen (HLA)-DQ2 or HLA-DQ8. Upon gluten
presentation, CD4þ T cells produce, among other things, inter-
leukin (IL)-21 and interferon-gamma (IFN-c). This leads to gluten-
specific antibody production by B cells and, in concert with IL-15
production by intestinal epithelial cells (IECs), activation of
intraepithelial lymphocytes (IELs), which attack the IECs, leading to
villous atrophy.
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but it has been a matter of debate whether destruction
of the barrier is only a consequence of the inﬂammatory
immune response, or whether there is a primary defect
in barrier function that contributes to disease develop-
ment.11 Several observations, including genetic associ-
ations,18,20 suggest a primary barrier defect. CeD
patients as well as their relatives have a higher lactu-
lose:mannitol ratio in their urine after intake of this
sugar solution when compared with control individuals
and patients with aspeciﬁc gastrointestinal symptoms.32
It has also been reported that the morphology of tight
junctions is altered in the epithelial barrier of children
with active CeD, and this is only partly restored on a
gluten-free diet.35 This is consistent with a report
describing altered expression and localization of epithe-
lial tight junction proteins in CeD patients on a gluten-
free diet.36 Lastly, quantitative measures of barrier
function, such as transepithelial electrical resistance
(TEER), are decreased in biopsies of active CeD
patients compared with healthy individuals, and this
was only partially restored on gluten-free diet.11
Current models for CeD
To date, there is no model system that fully recapitu-
lates the complexity of CeD. Current in vitro models
include immortalized cell lines and mucosal biopsies.
The immune system has been investigated using cell
lines of monocytes, such as THP-1, or intestinally
derived T cells.37,38 Existing data on epithelial barrier
function are largely based on intestinal mucosal biop-
sies or Caco-2, a tetraploid human colonic epithelial
cancer cell line. Immortalized cell lines do not represent
the genetics of CeD and have poor genomic integrity
(Table 1). Patient-derived intestinal biopsy material
does contain the CeD-associated genetic background
and directly reﬂects the disease phenotype, but is
scarce because of its invasive nature. Biopsies also
have limited proliferative capacity, and individual cell
types are diﬃcult to study within a heterogeneous
biopsy. Conventional systems to measure barrier func-
tion and transport, like transwell systems, do not recap-
itulate the intestinal physiology (e.g. IECs fail to form
villus-like structures or produce mucus), and co-cul-
tures with microbial cells are diﬃcult in these static
systems because of rapid overgrowth and contamin-
ation.39 Studying CeD in vivo is dependent on huma-
nized mouse models that express human HLA-DQ8 or
HLA-DQ2.40–42 These models have shown that the
presence of gluten-speciﬁc CD4þT cells is not suﬃ-
cient to induce CeD-like pathogenesis and that triggers
of the innate immune system, particularly IL-15
Table 1. Possible biological systems for modeling complex diseases: advantages and disadvantages.
Biological system

















No High Established Single cell type No þ Potentially easier to handle
 Poor genomic integrity





No High Established Multiple cell types Yes þ Whole organism: presence of
hormone, neurologic, and
metabolic signals from other
organs or cell systems
 Requires thorough understanding of
induction of disease
 Difficult to translate to humans
because of interspecies differences




Yes High Established Single cell type Yes þ Suitable for genotype selection
(patient and control cases)
 Requires knowledge of
differentiation to relevant tissue
aProviding identical genetic background.
bInvasive procedure necessary, extremely limited ‘‘healthy’’ control samples.
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overexpression, are essential for inducing intestinal
damage upon gluten exposure. However, mice are not
ideal models because of diﬀerences in intestinal tract
physiology,43 immune system44 and microbiome com-
position.45 To further elucidate the mechanisms under-
lying CeD, it is essential to capture the entire
pathobiology of CeD using multicellular and human-
based models.
Novel technologies that allow CeD-on-chip
Novel advances in human stem cell biology and micro-
ﬂuidics technology now allow for the development
of in vitro model systems with the desired genetic
background, environmental factors, and interaction
between disease-relevant cell types under physiological
conditions.
hiPSC and organoid technology
hiPSCs can be generated from diﬀerent types of som-
atic cells taken from any donor. hiPSCs can divide
indeﬁnitely and have the potential to diﬀerentiate into
any of the cell types found in the human body. In 2006,
Yamanaka and colleagues demonstrated for the ﬁrst
time that human and mouse ﬁbroblasts could be repro-
grammed to a pluripotent state, resembling embryonic
cells in culture.46,47 Pluripotency was achieved by viral
overexpression of only four transcription factors: Oct4,
Sox2, Klf4 and c-Myc. With the development of
improved protocols, hiPSC lines can now be eﬃciently
generated from urine-derived epithelial cells and blood-
derived erythroblasts, among others.48
Using knowledge on embryonic development, hiPSCs
can be diﬀerentiated into human intestinal organoids
(HIOs): miniature parts of the gut that are cultured in a
dish. The ﬁrst HIOs were grown from intestinal crypts
derived from human biopsy material.49 When cultured
in an extracellular matrix (ECM) gel in the presence of
speciﬁc growth factors, it is possible to maintain the stem
cell niche and the proliferative and diﬀerentiation capacity
of crypt cells in vitro, allowing them to grow out into
complex three-dimensional (3D) ‘‘budding’’ structures.
These structures containmultiple functional IEC subtypes
that can be kept in culture for prolonged periods of time.50
The generation of HIOs from hiPSCs is more complex
and leads to a less mature diﬀerentiated phenotype.51
However, embryonal development of intestinal tissue
can bemimicked by exposing hiPSCs to a series of speciﬁc
growth factors in a strict time-dependent manner.52
The HIO system still has limitations when it comes
to studying multifactorial diseases.53,54 HIOs are incon-
sistent in size and shape and are cultured in a static
system (embedded in extracellular matrix) that does
not recapitulate the intestine’s physical environment
(including ﬂuid ﬂow and peristaltic movement). The
closed conﬁguration of HIOs renders them less ideal
for studying transport over the intestinal barrier or
interactions with commensal microbes or pathogens
(Figure 2). Apical access can be achieved by microinjec-
tion,55 but this technique is labor intensive and technic-
ally challenging. The wide range of organoid sizes
complicates this procedure even more and makes it
nearly impossible to standardize the cell:stimulus
ratio. Additionally, dead cells accumulate in the
enclosed lumen of the HIO, ultimately impairing the
viability of the system. Lastly, physiological inter-
actions with other components of the intestine (e.g.
immune and vascular system) are diﬃcult to emulate
within the extracellular matrix, while the matrix is
necessary to generate and maintain HIOs. These limi-
tations can be overcome by an organ-on-chip system.
Intestine-on-chip
Organ-on-chip systems are microﬂuidic devices in
which cells are cultured in continuously perfused micro-
channels engineered to mimic the physical microenvir-
onment of tissues and organs.53 A current model makes
use of a chip containing two parallel hollow channels
approximately 1mm wide separated by a porous ECM-
coated membrane56 (Figure 3). In this device, a mono-
layer of IECs can be grown on the upper surface of the
membrane separating both channels, while endothelial
cells can be grown on the other side, representing blood
vessels. The culture media for the cells is delivered via
the upper and lower channel, which can also be used to
introduce metabolites, cytokines, microbial cells and/or
immune cells into the system. The system also provides
mechanical forces to simulate the physical microenvir-
onment of the intestine through ﬂuid ﬂow that intro-
duces shear stress on the cells and two vacuum
compartments on the sides that create a peristalsis-
like motion. Remarkably, these mechanical forces
induce epithelial cells to spontaneously form polarized
3D villus-like structures that contain cells expressing
markers characteristic of diﬀerentiated IECs (i.e.
adsorptive enterocytes, mucus-producing goblet,
Paneth and enteroendocrine cells).39,57–59 The resulting
epithelial layer exhibits basic functional properties,
such as mucus production, high barrier resistance,
activity of brush border and drug-metabolizing
enzymes, and high eﬃciency in nutrient uptake because
of the increased intestinal surface. These characteristics
allow for studies focusing on digestion and nutrient
uptake, barrier integrity and drug metabolism,39,57,58
and for co-cultures with commensal microbial cells
for extended periods of time (up to weeks).39,60
In accordance with the morphological changes, the
transcriptional proﬁle of epithelial cells cultured in the
470 United European Gastroenterology Journal 7(4)
dynamic chip system is very diﬀerent from that of cells
cultured in static Transwell systems or compared with
HIO. In fact, the intestine-on-chip proﬁle most resem-
bles the proﬁle of the corresponding in vivo intestinal
segment.58,60
The material most often used for chip fabrication,
polydimethylsiloxane, is fully transparent, making the
chip readily amenable to microscopy. For research pur-
poses, sophisticated intestine-on-chip systems can be
engineered to contain sensors, for example to measure
TEER.61 Integrated sensors are a major step forward
because they allow for continuous monitoring of the
system, something that is very diﬃcult and laborious
in conventional culture systems.
hiPSCs, HIOs and intestine-on-chip to model CeD
In contrast to monogenic diseases in which a single
gene is involved, genetic modeling of complex diseases
like CeD requires the inclusion of the many disease-
associated genetic risk factors that need to be studied
in the disease-relevant cell or tissue.19 Combining
hiPSC and HIO technology, in vitro models of the
intestine can be created from cells that contain the spec-
trum of CeD-associated genetic risk factors (Table 1).
Because hiPSC lines can be generated from relatively
easily accessible somatic cells such as urine-derived epi-
thelial cells, skin-derived ﬁbroblasts or blood-derived
erythroblasts,48 there is no dependency on intestinal
biopsy material obtained by invasive endoscopic pro-
cedures (in the case of CeD). This facilitates the collec-
tion of starting material from both patients and healthy
individuals. Varied genetic backgrounds can then be
studied to contrast the disease genetic background
with low risk backgrounds (Figure 4). To study speciﬁc
elements of the disease process, like barrier function,
genetic engineering can be used to perturb the system
by creating extreme genotypes (i.e. gene knock-out by
CRISPR/Cas9 technology). These technologies could
be used to generate isogenic hiPSC lines that contain
Inconsistency in size 
and shape









Figure 2. Limitations of the intestinal organoid system. Intestinal organoids are inconsistent in size and shape, which introduces vari-
ability in the results (see left panel). The closed configuration makes it technically challenging to access the lumen (apical side) of the
organoids. This limits studies into interactions between intestinal epithelial cells and micro-organisms (such as commensal microbes or
pathogens), studies into transepithelial transport (e.g. fluorescein isothiocyanate-dextran translocation as a measure of intestinal per-
meability) and analysis of luminally secreted components (see middle panel). Intestinal organoids are cultured in a static three-
dimensional system as they are embedded in an extracellular matrix, which does not reflect the dynamic environment of the human






Figure 3. Schematic presentation of a microengineered intestine-
on-chip. Intestine-on-chip systems often consist of a top
microfluidic channel, resembling the gut lumen, and a bottom
microfluidic channel, resembling the lamina propria and vascu-
lature. The channels are separated by a porous membrane on
which epithelial cells can be seeded and are flanked by vacuum
chambers to simulate peristalsis-like movements. Unidirectional
fluid flow through the microfluidic channels and contractions of the
vacuum chambers simulate the physical microenvironment of the
human intestine. The intestine-on-chip presented here is based on
the design of Emulate Inc, Boston, MA, USA.
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identical genetic background, except for, for instance, one
repaired CeD-associated genetic risk factor. Such iso-
genic lines may reveal the functional consequences of a
single genetic variation associated with CeD. Using
hiPSCs as a starting point, the eﬀect of a disease-
associated genotype can be evaluated in multiple disease-
relevant cell types, either individually or in combination,
in an intestine-on-chip. This model is unique because it
integrates (1) the CeD-associated genetic background, (2)
the interaction between disease-relevant cell types, (3) any
relevant environmental stimuli and (4) the physicalmicro-
environment of the intestine in a complex yet controllable
manner. Very recently, proof-of-concept was provided
for an hiPSC-derived intestinal epithelial-layer-on-
chip.59 This system now needs to be adapted toward a
more CeD-relevant model that includes hiPSC-derived
endothelial62 and immune cells.63–65
Future outlook
Improved understanding of CeD etiology
A CeD intestine-on-chip model can help address signiﬁ-
cant questions. It will allow the investigation of the inter-
action between IELs and IECs in the presence or
absence of triggering environmental factors. In particu-
lar, the IL-15 expression by IECs implicated in activa-
tion of IELs14 can be monitored in response to these
diﬀerent stimuli. A possible primary defect in intestinal
barrier function, which in turn alters gluten transport,
can be addressed using diﬀerent assays in a simple
system in which iPSC-derived IECs are present outside
the immune context (Figure 5(a)). With this system,
genes involved in the process can be identiﬁed. The
role of the gut microbiome in CeD pathogenesis can
also be studied. One can envision that the microbiota
aﬀects barrier function, but also that CeD-associated
genetics aﬀect microbiome homeostasis by altering the
immune response. Finally, the eﬀect of diﬀerent envir-
onmental factors can be studied by introducing them
into the system, for instance introducing viral ligands,
metabolites produced by CeD-associated microbiota, or
ATIs. The complexity of the system can be also adjusted
to ﬁt the research question, ranging from one cell type to
more complex systems (Figure 5(b)).
Development and testing of novel treatments
A lifelong adherence to a gluten-free diet has a pro-
found impact on everyday life, which makes treatments
to inhibit the strong pro-inﬂammatory immune
response to gluten very valuable. A physiologically rele-
vant CeD intestine-on-chip model can be used to test
novel drug candidates and existing drugs for reposition-
ing. By using patient-derived hiPSCs, diﬀerences in gen-
etic background that may aﬀect drug eﬃcacy can be
taken into account. To be used for drug screening
and/or addressing pharmacogenetic questions, high-
Increased genetic risk  
Healthy  individuals  





Somatic cells  
CRISPR/Cas9 
Intestine -on -chip  
Figure 4. The steps from patient or healthy individual to human induced pluripotent stem cell (hiPSC)-derived intestinal organoids and
intestinal barrier-on-chip. The large population and patient biobanks that have been constructed worldwide contain genomic data and
stored biological material, which allow for the selection of patient and healthy control material based on genetic makeup. hiPSCs can be
derived from stored kidney epithelial cells from urine or from erythroblasts from stored peripheral blood mononuclear cell fractions.
These materials are obtained in a minimally invasive manner. The hiPSC lines can then be differentiated into human intestinal organoids
(HIOs), which can subsequently be seeded on a microfluidic intestine-on-chip system to form an intestinal-barrier-on-chip. Specific
genetic factors can be studied by genetic engineering of hiPSCs using CRISPR/Cas9 technology. For example, CeD-associated risk alleles
can be reverted to protective alleles.
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throughput systems should be developed, as current
devices are still low throughput and costly.66
Nevertheless, an intestine-on-chip has great potential
for personalized medicine, providing a model that can
include an individual’s genetic background, relevant
cell types and environmental triggers.
Toward a patient-on-chip
Although CeD is regarded as a disease of the intestine,
the disease presents systemically.6 To capture the extra-
intestinal phenotypes, diﬀerent organ-on-chip systems
could be coupled in the future. In the context of CeD, a
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Figure 5. Research opportunities using a human induced pluripotent stem cell (hiPSC)-derived intestine-on-chip. (a) Functioning of the
intestinal epithelial barrier in patients with celiac disease (CeD) can be assessed with the intestine-on-chip system by performing different
assays: (1) Tight junctions and adherence junctions can be labeled and visualized on-chip using microscopy. (2) Barrier permeability can
be assessed by measuring transepithelial passing of fluorescein isothiocyanate (FITC)-dextran complexes. (3) Barrier integrity can be
tested by incorporating electrodes on-chip to measure transepithelial electrical resistance (TEER). (4) The passing of gluten peptides
across the barrier and the direct effect of gluten peptides on the intestinal epithelial cells can be analyzed. (5) The effect of CeD-associated
cytokines on the barrier can be analyzed by introducing the cytokines at the basolateral side (bottom channel). (b) Integration of gut
microbiome, endothelial cells and immune cells in the intestine-on-chip. hiPSC-derived epithelial layers-on-chip can be extended with
microbiomes from CeD patients or healthy controls on the apical side to assess the interactions between the epithelial layer and bacteria.
hiPSC-derived endothelial cells can be introduced at the basolateral side to mimic the vascular system. Additionally, peripheral blood
mononuclear cell (PBMC)- or hiPSC-derived immune cells can be introduced at the basolateral side to mimic the immune system.
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ﬁrst expansion might be to couple an intestine-on-chip
to a brain-on-chip. The intestine-brain-axis is of par-
ticular interest because the clinical spectrum of CeD
includes behavioral changes such as anxiety, depression
and fatigue.67,68 The mechanism underlying this ‘‘cross-
talk’’ between intestine and brain is poorly understood,
but proposed explanations include the interaction of
gluten peptides with endorphin receptors in the brain,
the migration of activated immune cells to the brain69
and detrimental eﬀects of circulating microbial metab-
olites70,71—all processes that could be tested by linking
organ-on-chip systems.
Conclusion
The development of a CeD-speciﬁc intestine-on-chip
model that closely recapitulates human intestinal physi-
ology will enable in vitro studies of CeD etiology in a
near in vivo situation. This will yield new insights into
the role of genetic and environmental factors in CeD
and may accelerate the search for novel treatments.
Because genetic diﬀerences among CeD patients could
be taken into account in the development of novel
treatments, the eﬃcacy of a treatment could be more
accurately predicted for each individual. Moreover, this
technology may improve diagnostic capacity by iden-
tifying new diagnostic markers for individuals at high
risk for CeD.
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